ARTICLES

Halogen-Bond-Promoted Direct Cross-Coupling of 2-Bromo- propionitrile Derivatives with Coumarins/Quinolinones: Synthesis and Transformation

  • Jilin Wen a ,
  • Peng Guo a ,
  • Guoliang Pu a ,
  • Xueyu Man , b, * ,
  • Chun-Yang He , a, *
Expand
  • a Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, School of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563000
  • b School of Pharmaceutical Sciences, Hunan University of Medicine, Huaihua, Hunan, 418000

Received date: 2025-04-08

  Revised date: 2025-06-05

  Online published: 2025-07-14

Supported by

National Natural Science Foundation of China(22461050)

National Natural Science Foundation of China(22161054)

the Science and Technology Department of Guizhou Province(No.QKHPTRC-CXTD2022-012)()

Abstract

A halogen bond-promoted cross-coupling reaction between 2-bromopropionitrile derivatives and coumarin/quino- linone compounds was reported. The developed methodology features a simple reaction system, mild conditions, and provides target products in moderate to good yields. The cyano functional group in the obtained compounds could be efficiently converted into 2H-tetrazole derivatives under mild conditions. Comparative studies using ester analogs demonstrated significantly reduced reactivity compared to their cyano counterparts, highlighting the crucial role of the cyano group in this transformation. Preliminary cellular experiments revealed that compound 4b selectively inhibited MDA-MB-231 cells with an IC50 value of (22.8±1.3) μmol/L, while most other compounds exhibited non-toxic or low toxicity toward both tumor cells and HL-7702 normal cells. These findings establish a foundation for further investigations into other biological activities such as antioxidant and antibacterial properties.

Cite this article

Jilin Wen , Peng Guo , Guoliang Pu , Xueyu Man , Chun-Yang He . Halogen-Bond-Promoted Direct Cross-Coupling of 2-Bromo- propionitrile Derivatives with Coumarins/Quinolinones: Synthesis and Transformation[J]. Chinese Journal of Organic Chemistry, 2025 , 45(12) : 4405 -4416 . DOI: 10.6023/cjoc202504009

腈类化合物(RCN)以其碳-氮叁键为特征, 广泛存在于天然产物和生物活性分子中(图1a)[1]. 此外, 氰基能够进行多种化学转化[2], 如氰基可以用于构建多种含氮杂环, 而含氮杂环在新药研发中有着重要的应用[3].
图1 (a)部分含氰基的药物; (b)以香豆素为核心结构的药物分子

Figure 1 (a) Drugs containing a cyano group; (b) coumarin-based drug molecules

另一方面, 香豆素和喹啉酮作为一类重要的杂环结构, 是多种天然产物和具有生物活性的分子的核心骨架, 并表现出了抗凝[4]、抗菌[5]、抗炎[6]、抗癌[7]以及抗人类免疫缺陷病毒(HIV)[8]等多种生物活性(图1b). 在这一背景下合成这些骨架的衍生物, 从而得到具有较高生物活性的分子引起了药物学家广泛的兴趣. 因此, 发展高效、简洁的方法合成香豆素和喹啉酮的衍生结构是十分必要的. 尽管, 最近十年对这些结构衍生物的合成取得了较大的进展[9,10], 但是由于进行烷基化反应时容易产生攫氢或者消除的副反应, 因此对于香豆素/喹啉酮的直接烷基化反应依然相对较少[10]. 为拓展该类化合物的结构多样性, 我们致力于发展高效的方法引入连有不同基团的烷基, 为后续的生物活性研究提供物质基础.
前期的研究表明, 将氰基及其衍生物连接到香豆素或其类似物上是可以生成具有较高生物活性的分子[11], 但这类化合物的结构多样性仍受限于合成方法[12], 从而限制了其在药物研发中的进一步应用. 最近, 我们[10g-10h]开发了一种实用的方法, 利用卤键的非共价相互作用, 在光诱导下实现了三氟甲基化烷基溴/3-溴-3-烷基-2,2-二氟丙酸乙酯与香豆素/喹啉酮的直接交叉偶联反应. 进一步研究发现, 部分产物具有显著的抗肿瘤活性. 为了进一步改造目标分子结构, 考虑到氰基在药物化学中的广泛应用及其对合成转化的调控能力, 拟将氰基引入目标分子中. 由于氰基是强吸电子基团, 它能增强相邻碳上溴原子参与的卤键作用[13], 从而更容易在光照下发生C—Br键的转化. 在本研究中, 将2-溴丙腈衍生物作为底物, 在光照下使其与香豆素和喹啉酮进行交叉偶联反应. 这种方法能够在香豆素/喹啉酮环上直接引入连有不同的烷基腈, 丰富香豆素/喹啉酮衍生物的种类, 方便后续的生物活性研究(Scheme 1).
图式1 反应设计

Scheme 1 Reaction design

1 结果与讨论

为了验证设想, 选择2-溴-4-(4-甲氧基苯基)丁腈(1a)和香豆素(2a)为模板底物, 考察了溶剂、电子给体、光源波长、1a2a的投料比以及反应时间对反应的影响. 如表1所示, 在410~415 nm的紫色LED灯照射下, 化合物1a2a的投料比为1∶5, 二甲亚砜(DMSO)为溶剂, 4-二甲氨基吡啶(DMAP, 2.0 equiv.)为卤键的电子给体, 在反应12 h后产物收率为52%. 经过分析发现化合物1a的攫氢产物(1a-H, 22%)和自偶联产物(1a-HC, 15%)为主要的副产物(详情见辅助材料). 随后的溶剂优化显示, 只有N,N-二甲基甲酰胺(DMF)能得到31%的收率, 而其他测试溶剂均未发生反应(表1, Entries 2~6). 进一步评估了各种卤键的电子给体化合物, 如三苯基膦(PPh3)、汉斯酯(HE)、苯酚(PhOH)、三乙胺(Et3N)、1,8-二氮杂双环[5.4.0]十一-7-烯(DBU)和N,N-二异丙基乙胺(DIPEA)(表1, Entries 7~12), 但均未提高反应效率. 不同光的波长研究也未发现更优的反应波长(表1, Entries 13~14). 当香豆素的用量减少时产率相应降低(表1, Entry 15), 而增加香豆素的用量则可显著提高产率(表1, Entries 16~17), 使用10 equiv.的2a时, 分离产率达到 68%. 需要指出的是, 在产物分离过程中, 过量的香豆素可以很容易地回收, 大大提高了香豆素的利用率. 将反应时间延长至24 h, 并不能进一步提高收率(表1, Entry 18). 对照实验表明, 没有DMAP或光照时反应无法进行, 表示它们在该过程中起到了关键作用(表1, Entries 19~20). 通过上述条件筛选, 确定了最优反应条件: 2-溴丙腈衍生物(1a, 1.0 equiv.), 香豆素(2a, 10.0 equiv.), DMAP (2.0 equiv.)为卤键的电子给体化合物, DMSO作为溶剂, 氩气氛围下10 W紫光(410~415 nm)照射反应12 h.
表1 1a与香豆素(2a)交叉偶联反应优化结果a

Table 1 Representative results for the optimization of cross-coupling between 1a and coumarin (2a)a

Entry Electron donor LED light/nm Solvent Yieldb/%
1 DMAP 410~415 DMSO 52
2 DMAP 410~415 DCM N. D.
3 DMAP 410~415 THF N. D.
4 DMAP 410~415 CH3OH N. D.
5 DMAP 410~415 DMF 31
6 DMAP 410~415 CH3CN N. D.
7 PPh3 410~415 DMSO N. D.
8 HE 410~415 DMSO N. D.
9 PhOH 410~415 DMSO N. D.
10 Et3N 410~415 DMSO 44
11 DBU 410~415 DMSO Trace
12 DIPEA 410~415 DMSO 16
13 DMAP 390~395 DMSO 38
14c DMAP 440~445 DMSO 49
15d DMAP 410~415 DMSO 41
16e DMAP 410~415 DMSO 58
17f DMAP 410~415 DMSO 68
18g DMAP 410~415 DMSO 69
19 410~415 DMSO N.D.
20h DMAP DMSO N.D.

a Reaction conditions (unless otherwise specified): 1a (0.1 mmol, 1.0 equiv.), 2a (0.5 mmol, 5.0 equiv.), electron donor compound (2.0 equiv.), solvent (0.5 mL), purple LED (410~415 nm 10 W), 30 ℃, 12 h; N.D.=Not Detected. Trace=The yield is very low. b The number in parentheses is the yield of isolated product. c blue LED (440~445 nm 10 W), 30 ℃, 12 h. d 3.0 equiv. of 2a. e 8.0 equiv. of 2a. f 10.0 equiv. of 2a, 12 h. g 10.0 equiv. of 2a, 24 h. h Without light.

在最优条件下, 首先研究了该反应体系与各种2-溴丙腈衍生物的底物适用性(Scheme 2). 具有电子中性取代基的底物(3b~3c)和具有富电子取代基的底物(3d)表现出良好的适用性, 能以中等收率得到目标产物. 三氟甲氧基在该转化中也是适用的, 收率为48% (3e). 缺电子取代基(如三氟甲基)的底物得到更高的收率, 收率可达70% (3f). 双苯基取代的底物收率则可以达到84% (3g). 带有环己基或四氢吡喃基的底物同样能以较高收率得到目标产物(3h, 收率74%; 3i, 收率86%). 环戊烷和金刚烷取代的化合物也是合适的底物, 能以中等收率(3j, 收率68%; 3k, 收率53%)得到目标产物. 为了进一步验证这一反应的实用性, 对生成化合物3a的克级反应也进行了研究, 发现产率稍微有所降低(收率59%).
图式2 化合物1与香豆素(2a)交叉偶联反应的底物适用性考察a

Scheme 2 Investigation of substrate scope in the cross-coupling reaction of compound 1 with coumarin (2a)

a Reaction conditions (unless otherwise specified): 1 (0.2 mmol, 1.0 equiv.), 2a (2.0 mmol, 10.0 equiv.), DMAP (2.0 equiv.), DMSO (1.0 mL), purple LED (410~415 nm 10 W), 30 ℃ 12 h. b Recovery ratio of coumarin. c 5.0 mmol scale.

随后, 对不同的香豆素和喹啉酮衍生物的底物适用性进行了考察. 如Scheme 3所示, 6/7-甲基香豆素(4b~4d)都能顺利转化, 以中等至良好的产率得到产物. 7-羟基香豆素及其相应的醚衍生物(4e~4h)表现出中等至较高的转化效率, 产率范围为48%~83%. 当使用6-溴香豆素作为底物时未观察到反应发生, 这可能是因为这一反应生成的烷基自由基是缺电子的, 因此和缺电子底物反应活性较差(4i). 此外, 喹啉酮衍生物(4j~4n)也能成功转化为目标产物, 获得了中等的产率.
图式3 化合物1'与杂环化合物(2)的交叉偶联反应的底物适用性考察a

Scheme 3 Investigation of substrate scope in the cross-coupling reaction of compound 1' with heterocycles (2)

a Reaction conditions (unless otherwise specified): 1 (0.2 mmol, 1.0 equiv.), 2 (2.0 mmol, 10.0 equiv.), DMAP (2.0 equiv.), DMSO (1.0 mL), purple LED (410~415 nm 10 W), 30 ℃, 12 h; N.D.=Not detected. b Recovery ratio of heterocycles. c 48 h. d 1.5 mL of DMSO.

为进一步验证氰基转化的多样性, 对氰基的衍生化也进行了研究. 由于2H-四唑是药物化学中一种重要的杂环结构, 如Scheme 4所示, 可以把氰基顺利地转化为2H-四唑, 并以良好的产率得到目标产物(5a~5c, 收率56%~61%).
图式4 氰基的衍生化研究a

Scheme 4 Derivatization study of the cyano group

a Reaction conditions (unless otherwise specified): 3/4 (0.2 mmol, 1.0 equiv.), ZnCl2 (0.25 mmol, 1.25 equiv.), TMSN3 (0.4 mmol, 2.0 equiv.), iPrOH (1.0 mL), 95 ℃, 4 h.

获得这些化合物后, 通过3-(4,5-二甲基-2-噻唑基)-2,5-二苯基-2H-四氮唑鎓溴化物(MTT)法对人乳腺癌腺癌细胞(MCF-7)、人骨肉瘤细胞(143B)、人三阴性乳腺癌细胞(MDA-MB-231)、人肺腺癌细胞(A549)和人肝细胞(HL-7702)测定了这些化合物的细胞的抑制浓度. 大多数化合物对受试细胞的半数最大抑制浓度(IC50)值大于50 μmol/L, 这表明这些化合物的细胞毒性较低或者无毒. 少数化合物表现出相对较好的抗癌活性和选择性. 例如, 化合物4b选择性地杀伤MDA-MB-231细胞, 其IC50值为(22.8±1.3) μmol/L, 而它对其他选定的癌细胞系和HL-7702细胞的IC50值均大于50 μmol/L, 表明化合物4b具有一定的抗癌活性和选择性(详见辅助材料).
为了进一步阐明这一转化的机理, 开展了一些实验. 在最优条件下加入2,2,6,6-四甲基哌啶-1-氧基自由基(TEMPO)后, 交叉偶联反应被抑制, 同时生成了被TEMPO捕获的化合物6 (Scheme 5a). 这一发现表明, 该反应过程中存在自由基中间体. 当把化合物1a中的溴原子替换成碘或者氯原子之后, 产率均有所下降, 分别以48%和15%的分离收率得到目标产物(Scheme 5b). 碘代物产率下降可能是由于自由基中间体生成速率加快, 导致副反应增多所致; 而氯代物产率显著降低, 则主要归因于碳-氯键断裂困难, 阻碍了反应的顺利进行. 随后, 将氰基替换为吸电子能力稍弱的酯基, 结果反应活性显著降低(8a~8c). 这一现象进一步凸显了氰基对反应的重要作用(Scheme 5c). 此外, 还进行了紫外-可见吸收光谱研究, 结果表明, 将化合物1a与4-二甲氨基吡啶(DMAP)混合后, 观察到在330 nm附近吸收显著增强(Scheme 5d, 具体细节参见辅助材料), 表明1a与DMAP之间存在卤键作用.
图式5 机理研究

Scheme 5 Mechanism research

基于这些初步发现以及我们之前的研究[10g-10h], 提出了关于这一转化反应的合理机理, 如Scheme 6所示. 首先, 2-溴丙腈衍生物与4-二甲氨基吡啶(DMAP)形成卤键(XB). 在可见光照射下生成烷基自由基(A). 随后, 该烷基自由基加成到杂环化合物(2)的碳-碳双键上, 形成自由基中间体(B). 接着, 该中间体被4-二甲氨基吡啶自由基氧化生成碳正离子(C). 最后, 碳正离子(C)通过β-H消除生成α,β-不饱和目标产物.
图式6 可能的反应机理

Scheme 6 Proposed mechanism

2 结论

开发了一种基于卤键作用的2-溴丙腈衍生物与香豆素/喹啉酮类化合物的交叉偶联反应. 该方法能方便地将不同的烷基腈引入到香豆素/喹啉酮结构单元之中, 并以中等至良好收率获得目标产物. 在所合成的化合物中, 氰基可进一步转化为2H-四唑杂环. 同时研究了酯类类似物的反应活性, 结合前期研究[10g-10h]发现, 此类反应吸电子基团对邻位C—Br键的活化能力顺序为: CF3>CF2COOEt>CN>COOMe. 初步细胞活性实验表明, 多数化合物对肿瘤细胞和HL-7702正常细胞均表现出无毒或者较低毒性. 上述初步的活性筛选结果, 为后续抗氧化、抗菌等其他生物活性的深入研究奠定了坚实基础.

3 实验部分

3.1 仪器与试剂

1H NMR和13C NMR图谱由Bruker-AVANCE NEO 400 MHz型光谱仪记录. 高分辨率质谱由Thermo Scientific LTQ记录. 光反应器为WATTCASTM的WP- TEC-1020SL型. 熔点使用SGW X-4熔点仪测定. 除非另有说明, 所有试剂均按商业来源提供的原样使用, 无需纯化直接使用.

3.2 实验方法

氩气保护下, 在装有磁性搅拌子的25 mL Schlenk管中, 加入化合物2 (2.0 mmol, 10.0 equiv.), DMAP (0.4 mmol, 2.0 equiv.). 然后加入超干DMSO (1.0 mL)和2-溴丙腈衍生物(0.2 mmol, 1.0 equiv.). 将反应管密封后, 置于10 W紫光(410~415 nm) LED灯照射下搅拌12 h, 此时温度约为30 ℃. 反应结束后, 加入100 mL乙酸乙酯, 并用饱和氯化钠溶液洗涤有机相. 合并有机层后用无水硫酸钠干燥, 通过减压浓缩得到粗品, 用硅胶层析分离对产物进行纯化, 得到相应的目标产物3/4.
将化合物3/4 (0.2 mmol,1.0 equiv.)、三甲基硅基叠氮(TMSN3, 0.4 mmol, 2.0 equiv.)和氯化锌(ZnCl2, 0.25 mmol, 1.25 equiv.)置于反应瓶中, 加入1.0 mL异丙醇(iPrOH), 于95 ℃搅拌3 h, 随后于室温继续反应12 h. 反应完成后, 减压除去溶剂, 所得绿色残留物用5 mL 5% NaOH水溶液搅拌处理30 min. 过滤生成的Zn(OH)2沉淀, 用5% NaOH水溶液洗涤. 所得澄清滤液用5 mol/L HCl调节pH至1, 析出白色固体. 将混合物冷却至0 ℃后过滤, 水洗, 减压干燥即得目标产物5.
氩气保护下, 在装有磁性搅拌子的25 mL Schlenk管中加入化合物2 (2.0 mmol, 10.0 equiv.), DMAP (0.4 mmol, 2.0 equiv.). 然后加入超干DMSO (1.0 mL)和化合物7a (0.2 mmol, 1.0 equiv.). 反应管密封后将其置于10 W紫光(410~415 nm) LED灯照射下搅拌12 h, 此时温度约为30 ℃. 反应结束后, 加入100 mL乙酸乙酯, 并用饱和氯化钠溶液洗涤有机相. 合并有机层, 用无水硫酸钠干燥, 通过减压浓缩得到粗品. 用硅胶层析分离对产物进行纯化, 得到相应的目标产物8.

3.3 化合物表征数据

4-(4-甲氧基苯基)-2-(2-氧代-2H-苯并吡喃-3-基)丁腈(3a): 产率为68%[43.2 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率90% (263.0 mg). 白色固体, m.p. 116~118 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.88 (s, 1H), 7.56~7.50 (m, 2H), 7.32~7.29 (m, 2H), 7.11 (d, J=8.4 Hz, 2H), 6.80 (d, J,=8.8 Hz, 2H), 4.03 (dd, J=9.2 Hz, J=4.8 Hz, 1H), 3.73 (s, 3H), 2.90~2.74 (m, 2H), 2.33~2.24 (m, 1H), 2.16~2.06 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.5, 158.1, 153.2, 140.3, 132.1, 131.2, 129.3, 128.0, 124.8, 123.4, 119.0, 118.3, 116.4, 113.9, 55.1 (d, J=4.2 Hz), 33.4, 32.3, 32.1. HRMS (ESI) calcd for C20H18O3N [M+H] 320.1281, found 320.1280.
2-(2-氧代-2H-苯并吡喃-3-基)-4-苯基丁腈(3b): 产率为59% [34.0 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率87% (254.3 mg). 白色固体, m.p. 105~107 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.93 (s, 1H), 7.59~7.53 (m, 2H), 7.35 (d, J=9.2 Hz, 2H), 7.29 (t, J=7.6 Hz, 2H), 7.24~7.18 (m, 3H), 4.10~4.07 (m, 1H), 2.98~2.83 (m, 2H), 2.40~2.31 (m, 1H), 2.20~2.10 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.7, 153.4, 140.5 (d, J=8.6 Hz), 139.3, 132.3 (d, J=13.4 Hz), 128.8, 128.6 (d, J=8.9 Hz), 128.2 (d, J=20.0 Hz), 126.6 (d, J=35.2 Hz), 125.0 (d, J=26.9 Hz), 123.6, 119.1, 118.4, 116.7 (d, J=27.1 Hz), 33.5, 33.2, 32.6 (d, J=21.2 Hz). HRMS (ESI) calcd for C19H16O2N [M+H] 290.1176, found 290.1175.
2-(2-氧代-2H-苯并吡喃-3-基)-4-(对甲苯基)丁腈(3c): 产率为55% [33.4 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率88% (257.2 mg). 白色固体, m.p. 104~106 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.91 (s, 1H), 7.56 (dd, J=17.6, 8.4 Hz, 2H), 7.36~7.31 (m, 2H), 7.10 (dd, J=11.2, 8.0 Hz, 4H), 4.08 (dd, J=9.2, 4.8 Hz, 1H), 2.94~2.79 (m, 2H), 2.37~2.31 (m, 1H), 2.28 (s, 3H), 2.19~2.10 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.7, 153.4, 140.4 (d, J=3.7 Hz), 136.2 (d, J=9.3 Hz), 132.3 (d, J=11.4 Hz), 129.5, 129.3 (d, J=14.6 Hz), 128.4 (d, J=13.6 Hz), 128.1 (d, J=13.6 Hz), 125.0 (d, J=21.8 Hz), 123.6, 119.1, 118.4, 116.7 (d, J=21.7 Hz), 33.5, 32.7 (d, J=6.1 Hz), 32.5, 21.0 (dd, J=8.8, 4.5 Hz). HRMS (ESI) calcd for C20H18O2N [M+H] 304.1332, found 304.1331.
4-(苯并[d][1,3]二氧杂环戊烯-5-基)-2-(2-氧代-2H-色烯-3-基)丁腈(3d): 产率为53% [35.2 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率87% (254.3 mg). 白色固体, m.p. 116~118 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.90 (s, 1H), 7.58~7.52 (m, 2H), 7.35~7.30 (m, 2H), 6.72~6.65 (m, 3H), 5.88~5.87 (m, 2H), 4.06 (dd, J=9.2, 4.8 Hz, 1H), 2.89~2.74 (m, 2H), 2.32~2.24 (m, 1H), 2.15~2.06 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.7, 153.4, 147.8, 146.2, 140.4, 133.0, 132.3, 128.1, 125.0, 123.6, 121.4, 119.1, 118.4, 116.7, 108.8, 108.4, 100.9, 33.6, 32.9, 32.4. HRMS (ESI) calcd for C20H16O4N [M+H] 334.1074, found 334.1072.
2-(2-氧代-2H-苯并吡喃-3-基)-4-(4-三氟甲基苯基)丁腈(3e): 产率为48% [35.9 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率75% (219.2 mg). 黄色固体, m.p. 68~70 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.93 (s, 1H), 7.57~7.52 (m, 2H), 7.35~7.30 (m, 2H), 7.23 (d, J=8.4 Hz, 2H), 7.11 (d, J=8.4 Hz, 2H), 4.09~4.05 (m, 1H), 2.97~2.82 (m, 2H), 2.38~2.29 (m, 1H), 2.18~2.09 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.6, 153.3, 147.8, 140.5 (d, J=7.6 Hz), 138.1, 132.3 (d, J=14.8 Hz), 129.7 (d, J=32.2 Hz), 128.1 (d, J=17.5 Hz), 125.0 (d, J=26.4 Hz), 123.3, 121.1 (d, J=34.9 Hz), 120.4 (q, J=258.1 Hz), 118.9, 118.3, 116.6 (d, J=27.4 Hz), 33.3, 32.6, 32.4; 19F NMR (376 MHz, CDCl3) δ: -57.92 (s, 3F). HRMS (ESI) calcd for C20H15O3NF3 [M+H] 374.0999, found 374.0998.
2-(2-氧代-2H-苯并吡喃-3-基)-4-(4-三氟甲氧基苯基)丁腈(3f): 产率为70% [49.9 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率88% (257.2 mg). 白色固体, m.p. 93~95 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.94 (s, 1H), 7.60~7.52 (m, 4H), 7.35~7.32 (m, 4H), 4.11~4.07 (m, 1H), 3.04~2.89 (m, 2H), 2.42~2.33 (m, 1H), 2.22~2.13 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.7, 153.4, 143.5, 140.6 (d, J=11.7 Hz), 132.6~132.4 (m), 128.9 (q, J=32.6 Hz), 128.8 (d, J=29.2 Hz), 128.2 (d, J=18.4 Hz), 125.7~125.4 (m), 125.1 (d, J=29.9 Hz), 124.1 (q, J=270.7 Hz), 123.2 (d, J=1.4 Hz), 118.9, 116.7 (d, J=30.2 Hz), 33.0 (d, J=8.5 Hz), 32.8, 32.6; 19F NMR (376 MHz, CDCl3) δ: -62.41 (s, 3F). HRMS (ESI) calcd for C20H15O2NF3 [M+H] 358.1049, found 358.1047.
2-(2-氧代-2H-苯并吡喃-3-基)-4,4-二苯基丁腈(3g): 产率为84% [61.1 mg, 洗脱液: V(石油醚)∶V(乙酸乙 酯)=15∶1], 香豆素回收率88% (257.2 mg). 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 7.85 (s, 1H), 7.56~7.53 (m, 1H), 7.48 (d, J=8.0 Hz, 1H), 7.43 (d, J=7.6 Hz, 2H), 7.39~7.28 (m, 5H), 7.24 (d, J=4.4 Hz, 4H), 7.16~7.10 (m, 1H), 4.35 (dd, J=11.2, 5.2 Hz, 1H), 3.95 (dd, J=10.4, 4.4 Hz, 1H), 2.93~2.86 (m, 1H), 2.46~2.39 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.6, 153.3, 143.4, 141.2, 140.4 (d, J=5.6 Hz), 132.2 (d, J=15.4 Hz), 129.2, 128.9, 128.5, 128.1 (d, J=27.7 Hz), 127.7, 127.3, 127.0 (d, J=8.5 Hz), 126.5, 124.9 (d, J=30.9 Hz), 123.6, 118.4, 116.6 (d, J=30.3 Hz), 49.3 (d, J=17.4 Hz), 37.7~37.2 (m), 32.2 (d, J=22.7 Hz). HRMS (ESI) calcd for C25H20- O2N [M+H] 366.1489, found 366.1488.
3-环己基-2-(2-氧代-2H-苯并吡喃-3-基)丙腈(3h): 产率为74% [41.8 mg, 洗脱液: V(石油醚)∶V(乙酸乙 酯)=20∶1], 香豆素回收率87% (254.3 mg). 白色固体, m.p. 135~137 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.92 (s, 1H), 7.57~7.52 (m, 2H), 7.35~7.30 (m, 2H), 4.13 (dd, J=10.4, 4.8 Hz, 1H), 1.90 (d, J=12.4 Hz, 1H), 1.80~1.56 (m, 7H), 1.32~1.13 (m, 3H), 1.04~0.95 (m, 2H); 13C NMR (101 MHz, CDCl3) δ: 159.8, 153.3, 140.0 (d, J=6.2 Hz), 132.2 (d, J=13.3 Hz), 128.1 (d, J=16.6 Hz), 124.9 (d, J=25.0 Hz), 124.7, 119.7, 118.6, 116.6 (d,J=25.8 Hz), 40.3, 35.8, 33.5 (d, J=14.4 Hz), 31.7 (d, J=11.5 Hz), 30.3 (d, J=20.0 Hz), 26.3~25.8 (m). HRMS (ESI) calcd for C18H20O2N [M+H] 282.1489, found 282.1488.
2-(2-氧代-2H-苯并吡喃-3-基)-3-(四氢-2H-吡喃-4-基)丙腈(3i): 产率为86% [49.6 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=20∶1], 香豆素回收率89% (260.1 mg). 白色固体, m.p. 163~165 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.92 (s, 1H), 7.58~7.52 (m, 2H), 7.34~7.30 (m, 2H), 4.14~4.11 (m, 1H), 3.99~3.92 (m, 2H), 3.39 (t, J=11.6 Hz, 2H), 1.90~1.74 (m, 4H), 1.65 (d, J=13.2 Hz, 1H), 1.42~1.31 (m, 2H); 13C NMR (101 MHz, CDCl3) δ: 159.7, 153.3, 140.2 (d, J=3.0 Hz), 132.2 (d, J=12.2 Hz), 128.1 (d, J=14.5 Hz), 125.0 (d, J=20.9 Hz), 124.1, 119.3, 118.4, 116.6 (d, J=21.4 Hz), 67.6~67.4 (m), 39.6, 33.3~32.9 (m), 31.8~31.5 (m), 29.9 (d, J=18.4 Hz). HRMS (ESI) calcd for C17H18O3N [M+H] 284.1281, found 284.1280.
3-环戊基-2-(2-氧代-2H-苯并吡喃-3-基)丙腈(3j): 产率为68% [36.2 mg, 洗脱液: V(石油醚)∶V(乙酸乙 酯)=20∶1), 香豆素回收率88% (257.2 mg). 白色固体, m.p. 88~90 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.92 (s, 1H), 7.58~7.53 (m, 2H), 7.36~7.31 (m, 2H), 4.07 (t, J=7.6 Hz, 1H), 2.14~2.03 (m, 1H), 1.95~1.80 (m, 4H), 1.70~1.51 (m, 4H), 1.30~1.12 (m, 2H); 13C NMR (101 MHz, CDCl3) δ: 159.8, 153.4, 140.0 (d, J=8.6 Hz), 132.2 (d, J=14.3 Hz), 128.1 (d, J=17.1 Hz), 125.0 (d, J=27.7 Hz), 124.5, 119.7, 118.6, 116.7 (d, J=27.5 Hz), 39.1, 38.2, 33.0, 32.4, 32.2, 31.7, 25.2. HRMS (ESI) calcd for C17H18- O2N [M+H] 268.1332, found 268.1331.
3-((3R,5R,7R)-金刚烷-1-基)-2-(-氧代-2H-苯并吡喃- 3-基)丙腈(3k): 产率为53% [35.2 mg, 洗脱液: V(石油醚)∶V(乙酸乙 酯)=20∶1], 香豆素回收率89% (260.1 mg). 白色固体, m.p. 171~173 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.92 (s, 1H), 7.56~7.52 (m, 2H), 7.34~7.29 (m, 2H), 4.10~4.06 (m, 1H), 2.00 (s, 3H), 1.73~1.62 (m, 13H), 1.55 (dd, J=14.0, 2.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.6, 153.3, 139.9 (d, J=7.0 Hz), 132.0 (d, J=15.0 Hz), 128.0 (d, J=17.1 Hz), 125.6, 124.9 (d, J=27.2 Hz), 121.0, 118.6, 116.6 (d, J=26.7 Hz), 47.8~47.4 (m), 42.1~41.8 (m), 36.9~36.5 (m), 33.0, 28.4 (d, J=9.7 Hz), 26.7, 26.5. HRMS (ESI) calcd for C22H24O2N [M+H] 334.1802, found 334.1799.
4-(4-(叔丁基)苯基)-2-(2-氧代-2H-苯并吡喃-3-基)丁腈(4a): 产率为64% [44.2 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率90% (262.7 mg). 白色固体, m.p. 84~86 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.92 (s, 1H), 7.59~7.53 (m, 2H), 7.36~7.30 (m, 4H), 7.16 (d, J=8.0 Hz, 2H), 4.12~4.09 (m, 1H), 2.96~2.81 (m, 2H), 2.40~2.32 (m, 1H), 2.22~2.12 (m, 1H), 1.28 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 159.7, 153.4, 149.4, 140.5, 136.3, 132.3, 128.1, 125.5, 124.9, 124.0, 123.6, 120.0, 118.4, 116.7, 34.4, 33.4, 32.7, 32.6, 31.4 (d, J=3.3 Hz). HRMS (DART) calced for C23H24O2N [M+H] 346.1802, found 346.1800.
4-(4-叔丁基苯基)-2-(6-甲基-2-氧代-2H-苯并吡喃-3-基)丁腈(4b): 产率为65% [46.8 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率88% (280.4 mg). 白色固体, m.p. 103~105 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.86 (s, 1H), 7.36 (d, J=8.8 Hz, 1H), 7.32~7.30 (m, 3H), 7.23 (d, J=8.4 Hz, 1H), 7.16 (d, J=8.0 Hz, 2H), 4.10 (dd, J=9.2, 4.8 Hz, 1H), 2.95~2.80 (m, 2H), 2.42 (s, 3H), 2.40~2.31 (m, 1H), 2.21~2.11 (m, 1H), 1.28 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 159.5, 152.1, 149.4, 140.4, 136.3, 134.7, 133.3, 128.1, 127.9 (d, J=9.4 Hz), 125.5, 123.4, 119.2, 118.2, 116.4, 34.4, 33.4, 32.7, 32.6, 31.4, 20.8 (d, J=4.4 Hz). HRMS (ESI) calcd for C24H25O2NNa [M+Na] 382.1778, found 382.1775.
4-(4-甲氧基苯基)-2-(6-甲基-2-氧代-2H-苯并吡喃-3-基)丁腈(4c): 产率为57% [38.2 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率90% (288.3 mg). 白色固体, m.p. 121~123 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.85 (s, 1H), 7.36 (d, J=8.4 Hz, 1H), 7.30 (s, 1H), 7.23 (d, J=8.4 Hz, 1H), 7.13 (d, J=8.4 Hz, 2H), 6.82 (d, J=8.4 Hz, 2H), 4.05 (dd, J=9.2, 4.8 Hz, 1H), 3.76 (s, 3H), 2.91~2.76 (m, 2H), 2.42 (s, 3H), 2.34~2.25 (m, 1H), 2.14~2.05 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 161.1, 158.2, 151.5, 140.4, 134.7, 133.3, 131.3, 129.4, 127.9, 123.4, 119.2, 118.2, 116.4, 114.0, 55.2, 33.7, 32.5, 32.3, 20.8. HRMS (DART) calcd for C21H20O3N [M+H] 334.1438, found 334.1436.
4-(4-叔丁基苯基)-2-(7-甲基-2-氧代-2H-苯并吡喃-3-基)丁腈(4d): 产率为78% [56.0 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率87% (278.7 mg). 白色固体, m.p. 87~89 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.88 (s, 1H), 7.41 (d, J=8.4 Hz, 1H), 7.31 (d, J=8.4 Hz, 2H), 7.17~7.13 (m, 4H), 4.11~4.07 (m, 1H), 2.95~2.80 (m, 2H), 2.46 (s, 3H), 2.39~2.30 (m, 1H), 2.21~2.11 (m, 1H), 1.29 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 160.0, 153.5, 149.3, 143.7, 140.4 (d, J=3.2 Hz), 136.3, 128.2, 127.8 (d, J=24.4 Hz), 126.2 (d, J=27.0 Hz), 125.5 (d, J=26.7 Hz), 122.3, 119.3, 116.8 (d, J=29.1 Hz), 116.0, 34.4, 33.4, 32.6 (d, J=6.7 Hz), 32.4, 31.3 (dd, J=26.3, 13.2 Hz), 21.9 (d, J=12.7 Hz). HRMS (DART) calcd for C24H26O2N [M+H] 360.1958, found 360.1957.
4-(4-(叔丁基)苯基)-2-(7-羟基-2-氧代-2H-苯并吡喃-3-基)丁腈(4e): 产率为48% [34.6 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=3∶1], 香豆素回收率79% (257.2 mg). 黄色固体, m.p. 183~185 ℃; 1H NMR (400 MHz, CD3OD) δ: 7.88 (s, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.26 (d, J=8.0 Hz, 2H), 7.10 (d, J=8.4 Hz, 2H), 6.80~6.77 (m, 1H), 6.68 (d, J=2.0 Hz, 1H), 4.01~3.98 (m, 1H), 2.87~2.70 (m, 2H), 2.26~2.16 (m, 2H), 1.24 (s, 9H); 13C NMR (101 MHz, CD3OD) δ: 163.1, 161.8, 156.4, 150.0, 142.6, 137.9, 130.7, 128.9, 126.2, 120.4, 119.3, 114.6, 112.5, 103.0, 34.9, 33.9, 33.4, 33.1, 31.6. HRMS (ESI) calcd for C23H23O3NNa [M+Na] 384.1570, found 384.1568.
4-(4-(叔丁基)苯基)-2-(7-甲氧基-2-氧代-2H-苯并吡喃-3-基)丁腈(4f): 产率为58% [43.2 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率83% (292.6 mg). 白色固体, m.p. 97~99 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.84 (s, 1H), 7.42 (d, J=8.8 Hz, 1H), 7.31 (d, J=8.4 Hz, 2H), 7.15 (d, J=6.8 Hz, 2H), 6.89 (dd, J=8.4, 2.4 Hz, 1H), 6.82 (d, J=2.4 Hz, 1H), 4.08~4.05 (m, 1H), 3.88 (s, 3H), 2.94~2.79 (m, 2H), 2.37~2.28 (m, 1H), 2.19~2.10 (m, 1H), 1.29 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 163.2, 160.1, 155.3, 149.3, 140.9, 137.5, 129.0 (d, J=7.2 Hz), 128.1, 125.6 (d, J=4.8 Hz), 119.8, 119.4, 113.2 (d, J=4.7 Hz), 112.1, 100.6 (d, J=4.0 Hz), 55.9 (d, J=11.2 Hz), 34.4, 33.5, 32.6, 32.5 (d, J=10.4 Hz), 31.4. HRMS (ESI) calcd for C24H26O3N [M+H] 376.1907, found 376.1906.
2-(7-甲氧基-2-氧代-2H-苯并吡喃-3-基)-4-(4-甲氧基苯基)丁腈(4g): 产率为59% [41.4 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率90% (317.1 mg). 黄色固体, m.p. 112~114 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.83 (s, 1H), 7.41 (d, J=8.8 Hz, 1H), 7.13 (d, J=8.8 Hz, 2H), 6.88 (dd, J=8.8, 2.4 Hz, 1H), 6.83~6.81 (m, 3H), 4.04~4.00 (m, 1H), 3.88 (s, 3H), 3.76 (s, 3H), 2.90~2.75 (m, 2H), 2.34~2.24 (m, 1H), 2.14~2.05 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 162.7, 160.1, 158.2, 155.3, 140.5, 131.4, 129.4 (d, J=8.0 Hz), 129.1 (d, J=8.2 Hz), 119.8, 119.4, 114.0, 113.2 (d, J=6.0 Hz), 112.1, 100.6 (d, J=5.2 Hz), 55.9 (d, J=12.2 Hz), 55.2 (d, J=10.8 Hz), 33.8, 32.4~32.3 (m), 29.7. HRMS (ESI) calcd for C21H20O4N [M+H] 350.1387, found 350.1386.
2-((3-(3-(4-叔丁基苯基)-1-氰基丙基)-2-氧代-2H-苯并吡喃-6-基)氧基)丙酸乙酯(4h): 产率为83% [76.5 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=10∶1], 香豆素回收率88% (461.6 mg). 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 7.84 (d, J=1.6 Hz, 1H), 7.43 (d, J=8.4 Hz, 1H), 7.30 (d, J=8.4 Hz, 2H), 7.15 (d, J=8.0 Hz, 2H), 6.91~6.87 (m, 1H), 6.76~6.74 (m, 1H), 4.81 (dd, J=13.6, 6.4 Hz, 1H), 4.26~4.21 (m, 2H), 4.05 (dd, J=9.2, 4.8 Hz, 1H), 2.93~2.78 (m, 2H), 2.36~2.27 (m, 1H), 2.18~2.08 (m, 1H), 1.67 (d, J=6.8 Hz, 3H), 1.28 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 171.0, 161.0, 159.9, 655155.0, 149.3, 140.3, 136.3, 129.2, 128.0, 125.5, 120.3, 119.3, 113.6 (d, J=12.8 Hz), 112.6, 101.7 (d, J=11.0 Hz), 72.8, 61.7, 34.3, 33.4 (d, J=3.0 Hz), 32.6, 32.4 (d, J=3.8 Hz), 31.3, 18.3, 14.1. HRMS (ESI) calcd for C28H32O5N [M+H] 462.2275, found 462.2270.
4-(4-叔丁基苯基)-2-(2-氧代-1,2-二氢喹啉-3-基)丁腈(4j): 产率为52% [35.5 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=13∶1], 香豆素回收率50% (144.3 mg). 白色固体, m.p. 203~205 ℃; 1H NMR (400 MHz, CDCl3) δ: 12.85 (s, 1H), 8.05 (s, 1H), 7.64 (d, J=8.0 Hz, 1H), 7.58 (t, J=8.4 Hz, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.34 (d, J=8.4 Hz, 2H), 7.29 (d, J=8.0 Hz, 1H), 7.22 (d, J=8.0 Hz, 2H), 4.35 (dd, J=9.2, 4.8 Hz, 1H), 2.99~2.89 (m, 2H), 2.49~2.40 (m, 1H), 2.28~2.19 (m, 1H), 1.31 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 162.5, 149.3, 138.3 (d, J=5.9 Hz), 138.0, 136.8, 131.1 (d, J=6.7 Hz), 128.3, 128.1, 127.5, 125.6, 125.4 (d, J=5.8 Hz), 123.3 (d, J=15.0 Hz), 120.2, 119.5, 116.0 (d, J=12.8 Hz), 34.5, 33.8, 32.7, 31.9 (d, J=7.8 Hz), 31.4 (d, J=7.8 Hz); HRMS (ESI) calcd for C23H25ON2 [M+H] 345.1961, found 345.1962.
4-(4-(叔丁基)苯基)-2-(7-羟基-2-氧代-1,2-二氢喹啉-3-基)丁腈(4k): 产率为52% [37.4 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=1∶1], 香豆素回收率83% (267.5 mg). 黄色固体, m.p. >220 ℃; 1H NMR (400 MHz, DMSO-d6) δ: 11.84 (s, 1H), 10.25 (s, 1H), 7.92 (s, 1H), 7.54 (d, J=8.4 Hz, 1H), 7.29 (d, J=8.0 Hz, 2H), 7.14 (d, J=8.0 Hz, 2H), 6.72 (d, J=2.0 Hz, 1H), 6.68~6.66 (m, 1H), 4.11 (dd, J=8.4, 6.4 Hz, 1H), 2.76~2.63 (m, 2H), 2.18~2.10 (m, 2H), 1.24 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ: 160.7, 160.0, 148.4, 140.3, 137.5, 137.2, 129.7 (d, J=16.1 Hz), 128.0 (d, J=25.9 Hz), 125.2 (d, J=24.3 Hz), 122.8, 120.7, 112.6, 111.5, 99.6 (d, J=8.9 Hz), 34.1, 33.3, 32.2, 31.2 (d, J=10.2 Hz), 30.7 (d, J=18.6 Hz). HRMS (ESI) calcd for C23H25O2N2 [M+H] 361.1911, found 361.1909.
2-(7-羟基-2-氧代-1,2-二氢喹啉-3-基)-4-(对甲苯基)丁腈(4l): 产率为31% [19.8 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=1∶1], 香豆素回收率80% (257.8 mg). 黄色固体, m.p. 112~114 ℃; 1H NMR (400 MHz, DMSO- d6) δ: 11.84 (s, 1H), 10.26 (s, 1H), 7.92 (s, 1H), 7.54 (d, J=8.4 Hz, 1H), 7.08 (s, 4H), 6.72 (s, 1H), 6.68 (d, J=8.0 Hz, 1H), 4.10~4.06 (m, 1H), 2.76~2.61 (m, 2H), 2.24 (s, 3H), 2.17~2.06 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ: 160.7, 160.0, 140.3, 137.5 (d, J=7.1 Hz), 137.1, 135.2, 129.8 (d, J=19.3 Hz), 129.1 (d, J=35.2 Hz), 128.2 (d, J=34.9 Hz), 122.8, 120.7, 112.2 (d, J=8.7 Hz), 112.1, 99.7 (d, J=13.8 Hz), 32.8, 32.3, 30.7 (d, J=21.4 Hz), 20.7. HRMS (ESI) calcd for C20H19O2N2 [M+H] 319.1441, found 319.1440.
4-(4-9叔丁基)苯基)-2-(1-甲基-2-氧代-1,2-二氢喹啉-3-基)丁腈(4m): 产率为44% [31.7 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=8∶1], 香豆素回收率89% (284.6 mg); 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 7.93 (s, 1H), 7.63~7.59 (m, 2H), 7.38 (d, J=8.0 Hz, 1H), 7.29 (t, J=8.4 Hz, 3H), 7.17 (d, J=8.0 Hz, 2H), 4.31 (dd, J=9.2 Hz, J=4.8 Hz, 1H), 3.75 (s, 3H), 2.95~2.81 (m, 2H), 2.40~2.31 (m, 1H), 2.17~2.08 (m, 1H), 1.29 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 160.4, 149.2, 139.4, 136.8, 136.4, 131.1, 129.0, 128.1, 127.5, 125.4, 122.7, 120.3, 119.7, 114.2, 34.4, 33.8, 32.8, 32.6, 31.4, 30.0. HRMS (ESI) calcd for C24H27ON2 [M+H] 359.2118, found 359.2117.
4-(4-甲氧基苯基)-2-(1-甲基-2-氧代-1,2-二氢喹啉-3-基)丁腈(4n): 产率为57% [37.9 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率90% (286.6 mg). 黄色固体, m.p. 103~105 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.92 (s, 1H), 7.62~7.58 (m, 2H), 7.37 (d, J=8.8 Hz, 1H), 7.28 (t, J=7.6 Hz, 1H), 7.15 (d, J=8.8 Hz, 2H), 6.82 (d, J=8.4 Hz, 2H), 4.28~4.24 (m, 1H), 3.76 (s, 3H), 3.74 (s, 3H), 2.92~2.78 (m, 2H), 2.35~2.26 (m, 1H), 2.13~2.04 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 160.4, 158.1, 139.4, 136.4, 131.8, 131.0, 129.4, 129.0, 127.5, 122.7, 120.3, 119.7, 114.2, 113.9, 55.2 (d, J=5.4 Hz), 34.1, 32.5, 30.0, 29.9. HRMS (ESI) calcd for C21H21- O2N2 [M+H] 333.1598, found 333.1596.
3-[3-(4-甲氧基苯基)-1-(1H-四唑-5-基)丙基]-2H-苯并吡喃-2-酮(5a): 产率为59% (42.8 mg). 白色固体, m.p. 95~97 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.88 (s, 1H), 7.56~7.50 (m, 2H), 7.32~7.29 (m, 2H), 7.11 (d, J=8.4 Hz, 2H), 6.80 (d, J=8.8 Hz, 2H), 4.03 (dd, J=9.2, 4.8 Hz, 1H), 3.73 (s, 3H), 2.90~2.74 (m, 2H), 2.33~2.24 (m, 1H), 2.16~2.06 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.5, 158.1, 153.2, 140.3, 132.1, 131.2, 129.3, 128.0, 124.8, 123.4, 119.0, 118.3, 116.4, 113.9, 55.1 (d, J=4.2 Hz), 33.4, 32.3, 32.1. HRMS (FI) calcd for C20H18O3N4Na [M+Na] 385.1271, found 385.1267.
3-[3-(4-(叔丁基)苯基)-1-(1H-四唑-5-基)丙基]-7-羟基-2H-苯并吡喃-2-酮(5b): 产率为56% (45.3 mg). 黄色固体, m.p. 176~178 ℃; 1H NMR (400 MHz, CD3OD) δ: 7.89 (s, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.25 (d, J=8.4 Hz, 2H), 7.09 (d, J=8.4 Hz, 2H), 6.80 (d, J=8.8 Hz, 1H), 6.68 (s, 1H), 4.01~3.97 (m, 1H), 2.87~2.69 (m, 2H), 2.24~2.16 (m, 2H), 1.23 (s, 9H); 13C NMR (101 MHz, CD3OD) δ: 163.1, 161.8, 156.4, 150.0, 142.8, 137.9, 130.7, 128.9, 126.2, 120.4, 119.3, 114.6, 112.5, 103.0, 34.9, 33.8, 33.4, 33.1, 31.6. HRMS (FI) calcd for C23H24O3N4Na [M+Na] 427.1741, found 427.1739.
3-[1-(1H-四唑-5-基)-3-(对甲苯基)丙基]-7-羟基喹啉-2(1H)-酮(5c): 产率为61% (44.2 mg). 黄色固体, m.p.>220 ℃; 1H NMR (400 MHz, DMSO-d6) δ: 11.83 (s, 1H), 10.29 (s, 1H), 7.91 (s, 1H), 7.54 (d, J=8.4 Hz, 1H), 7.08 (s, 4H), 6.72 (s, 1H), 6.68 (dd, J=8.4, 2.4 Hz, 1H), 4.09~4.05 (m, 1H), 2.76~2.61 (m, 2H), 2.23 (s, 3H), 2.17~2.06 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ: 160.8, 160.0, 140.3, 137.6, 137.2, 135.2, 129.8, 129.1, 128.3, 122.8, 120.7, 112.3, 112.1, 99.7, 32.8, 32.3, 30.7, 20.7. HRMS (FI) calcd for C20H19O2N5Na [M+Na] 384.1431, found 384.1426.
4-(4-(叔丁基)苯基)-2-(2-氧代-2H-苯并吡喃-3-基)丁酸甲酯(8a): 产率为52% [39.8 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率89% (260.1 mg). 白色固体, m.p. 78~80 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.67 (s, 1H), 7.53~7.46 (m, 2H), 7.34~7.28 (m, 4H), 7.13 (d, J=8.0 Hz, 2H), 3.92~3.88 (m, 1H), 3.72 (s, 3H), 2.69~2.65 (m, 2H), 2.45~2.36 (m, 1H), 2.22~2.13 (m, 1H), 1.29 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 173.2, 161.0, 153.2, 149.0, 139.9 (d, J=6.1 Hz), 137.7, 131.4 (d, J=5.2 Hz), 128.2~128.0 (m), 127.8 (d, J=9.2 Hz), 126.9, 125.4~125.3 (m), 124.5 (d, J=11.5 Hz), 119.1, 116.5 (d, J=11.0 Hz), 52.4 (d, J=12.2 Hz), 45.0 (d, J=13.7 Hz), 34.4, 33.1, 32.8, 31.4 (d, J=5.9 Hz). HRMS (ESI) calcd for C24H27O4 [M+H] 379.1904, found 379.1902.
4-(4-叔丁基苯基)-2-(7-甲氧基-2-氧代-2H-苯并吡喃-3-基)丁酸甲酯(8b): 产率为28% [22.7 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率87% (306.5 mg). 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 7.61 (s, 1H), 7.36 (d, J=8.4 Hz, 1H), 7.29 (d, J=8.0 Hz, 2H), 7.12 (d, J=8.0 Hz, 2H), 6.84 (d, J=8.4 Hz, 1H), 6.81 (s, 1H), 3.88~3.84 (m, 4H), 3.71 (s, 3H), 2.68~2.64 (m, 2H), 2.42~2.33 (m, 1H), 2.19~2.10 (m, 1H), 1.29 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 173.5, 162.5, 161.4, 154.9, 148.9, 140.1, 139.9, 137.8, 128.8 (d, J=25.6 Hz), 128.1 (d, J=30.0 Hz), 125.3 (d, J=27.1 Hz), 123.2, 112.8~112.6 (m), 100.5 (d, J=21.6 Hz), 55.8 (d, J=22.2 Hz), 52.3 (d, J=19.1 Hz), 44.7 (d, J=20.2 Hz), 34.4, 33.3, 33.0 (d, J=17.1 Hz), 31.4 (dd, J=27.8, 14.1 Hz). HRMS (ESI) calcd for C25H29O5 [M+H] 409.2010, found 409.2008.
4-(4-(叔丁基)苯基)-2-(2-氧代-1,2-二氢喹啉-3-基)丁酸甲酯(8c): 产率为12% [17.1 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=15∶1], 香豆素回收率89% (258.4 mg). 白色固体, m.p. 158~160 ℃; 1H NMR (400 MHz, CDCl3) δ: 12.46 (s, 1H), 7.80(s, 1H), 7.56 (d, J=8.0 Hz, 1H), 7.53~7.49 (m, 1H), 7.42 (d, J=8.0 Hz, 1H), 7.30 (d, J=8.0 Hz, 2H), 7.23 (t, J=8.0 Hz, 1H), 7.15 (d, J=8.0 Hz, 2H), 4.13~4.10 (m, 1H), 3.71 (s, 3H), 2.70 (t, J=8.0 Hz, 2H), 2.50~2.41 (m, 1H), 2.29~2.20 (m, 1H), 1.30 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 174.2, 163.6, 148.8, 138.3, 137.8, 137.7, 131.1, 130.3, 128.2, 127.7, 125.3, 122.7, 120.0, 116.0, 52.1, 44.4, 34.4, 33.2, 33.1, 31.4. HRMS (ESI) calcd for C24H28O3N [M+H] 378.2064, found 378.2062.
4-(4-甲氧基苯基)丁腈(1a-H): 产率为22% [3.8 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=14∶1]. 无色油状液体. 1H NMR (400 MHz, CDCl3) δ: 7.10 (d, J=8.0 Hz, 2H), 6.85 (d, J=8.0 Hz, 2H), 3.80 (s, 3H), 2.74~2.70 (m, 2H), 2.32~2.29 (m, 2H), 1.98~1.91 (m, 2H). HRMS (ESI) calcd for C11H13ONNa [M+Na] 198.0889, found 198.0888.
2,3-双(4-甲氧基苯乙基)丁二腈(1a-HC): 产率为15% [5.2 mg, 洗脱液: V(石油醚)∶V(乙酸乙酯)=6∶1]. 浅黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 7.06 (d, J=8.0 Hz, 4H), 6.84 (d, J=8.0 Hz, 4H), 3.79 (s, 6H), 2.88~2.83 (m, 2H), 2.72~2.60 (m, 4H), 2.25~2.16 (m, 2H), 1.94~1.85 (m, 2H); 13C NMR (101 MHz, CDCl3) δ: 158.5, 130.8, 129.4, 118.1, 114.3, 55.3, 33.3, 32.4, 31.9. HRMS (ESI) calcd for C22H24O2N2Na [M+Na] 371.1730, found 371.1722.
辅助材料(Supporting Information) 合成的化合物3~8, 1a-H1a-HC1H NMR、13C NMR、19F NMR和HRMS谱图. 这些材料可以免费从本刊网站(http://sioc- journal.cn/)上下载.
(Lu, Y.)
[1]
(a) Chen L.; Pu M.-P.; Li S.-Y.; Sang V X.-P; Liu X.-H.; Wu Y.-D.; Feng X.-M. J. Am. Chem. Soc. 2021, 143, 19091.

DOI

(b) Benedicto A. M.; Lucantoni F.; Fuster-Martínez I.; Diaz-Pozo P.; Dorcaratto D.; Muñoz-Forner E.; Victor V. M.; Esplugues J. V.; Blas-García A.; Apostolova N. Biomed. Pharmacother. 2024, 178, 117206.

DOI

(c) Flick A. C.; Ding H. X.; Leverett C. A.; Kyne R. E.; Liu K. K.-C.; Fink S. J.; O’Donnell C. J. Bioorg. Med. Chem. 2016, 24, 1937.

DOI

(d) Dhureja M.; Deshmukh R. Eur. J. Pharm. 2024, 975, 176635.

DOI

(e) Dong J.-Z.; Gong Y.-C.; Liu J.; Chen X.-F.; Wen X.-A.; Sun H.-B. Bioorg. Med. Chem. 2014, 22, 1383.

DOI

[2]
(a) Tulichala R. N. P.; Swamy K. C. K. Chem. Commun. 2015, 51, 12008.

DOI

(b) Liu Y.-X.; He S.-P.; Quan Z.-Y.; Cai H.-Z.; Zhao Y.; Wang B. Green Chem. 2019, 21, 830.

DOI

(c) Li J.-J.; Liu Y.-X.; Tang W.-J.; Xue D.; Li C.-Q.; Xiao J.-L.; Wang C. Chem.-Eur. J. 2017, 23, 14445.

DOI

(d) Chouhan K. K.; Chowdhury D.; Mukherjee A. Org. Biomol. Chem. 2023, 21, 2429.

DOI PMID

(e) Xie S.-M.; Cai F.-F.; Liu L.-X.; Su L.-B.; Dong J.-Y.; Zhou Y.-B. Chin. J. Chem. 2024, 42, 2299.

[3]
(a) Chen Y. F.; Hsieh J. C. Org. Lett. 2014, 16, 4642.

DOI

(b) Meda K. M.; Lesch R. W.; Edioma F. B.; Wrenn S. P.; Ndahayo V.; Mulcahy S. P. Org. Lett. 2020, 22, 3135.

DOI

(c) Kuang J.; Chen B.; Ma S. Org. Chem. Front. 2014, 1, 186.

DOI

(d) Bian Q.-L.; Wu C.-L.; Yuan J.-P.; Shi Z.-D.; Ding T.; Huang Y.-W.; Xu H.; Xu Y.-Q. J. Org. Chem. 2020, 85, 4058.

DOI

(e) Pieczykolan M.; Sadowski B.; Gryko D. T. Angew. Chem. Int. Ed. 2020, 59, 7528.

DOI PMID

[4]
(a) Frédérick R.; Robert S.; Charlier C.; Ruyck J.; Wouters J.; Pirotte B.; Masereel B.; Pochet L. J. Med. Chem. 2005, 48, 7592.

PMID

(b) Abdelhafez O.; Amin K.; Batran R.; Mahe T.; Nada S. Bioorg. Med. Chem. 2010, 18, 3371.

DOI

[5]
(a) Yang X.; Zeng C.; Avula S.; Peng X.; Geng R.; Zhou C. Eur. J. Med. Chem. 2023, 245, 114891.

DOI

(b) Liu J.; Zhao S.; Hu J.-Y.; Chen Q.-X.; Jiao S.-M.; Xiao H.-C.; Zhang Q.; Xu J.; Zhao J.-F.; Zhou H.-B.; Zheng J.-X.; Sun P.-H. J. Med. Chem. 2023, 66, 14735.

DOI

[6]
Yan N. L.; Santos-Martins D.; Nair R.; Chu A.; Wilson I. A.; Johnson K. A.; Forli S.; Morgan G. J.; Petrassi H. M.; Kelly J. W. J. Med. Chem. 2021, 64, 6273.

DOI

[7]
(a) Zhang L.-F.; Xu Z. Eur. J. Med. Chem. 2019, 181, 111587.

DOI

(b) Chilin A.; Battistutta R.; Bortolato A.; Cozza G.; Zanatta S.; Poletto G.; Mazzorana M.; Zagotto G.; Uriarte E.; Guiotto A.; Pinna L. A.; Meggio F.; Moro S. J. Med. Chem. 2008, 51, 752.

DOI

[8]
(a) Zhu M.; Ma L.; Wen J.-J.; Dong B.; Wang Y.-J.; Wang Z.; Zhou J.-M.; Zhang G.-N.; Wang J.-X.; Guo Y.; Liang C.; Cen S.; Wang Y.-C. Eur. J. Med. Chem. 2020, 186, 111900.

DOI

(b) Zhao H.; Neamati N.; Hong H.; Mazumder A.; Wang S.; Sunder S.; Milne G. W. A.; Pommier Y.; Burke T. R. J. Med. Chem. 1997, 40, 242.

PMID

[9]
(a) Reddy M. S.; Thirupathi N.; Babu M. H. Eur. J. Org. Chem. 2012, 29, 5803.

(b) Abdelhafez O.; Amin K.; Batran R.; Mahe T.; Nada S.; Sethumadhavan S. Bioorg. Med. Chem. 2010, 18, 3371.

DOI

[10]
For recent methods of alkylating coumarin, see: (a) Song H.-Y.; Liu M.-Y.; Huang J.; Wang D.; Jiang J.; Chen J.-Y.; Yang T.-B.; He W.-M.. J. Org. Chem. 2023, 88, 2288.

DOI

(b) Jafarpour F.; Darvishmolla M.; Azaddoost N.; Mohaghegh F. New J. Chem. 2019, 43, 9328.

DOI

(c) Gan X.; Wu S.; Geng F.; Dong J.; Zhou Y. Tetrahedron Lett. 2022, 96, 153720.

DOI

(d) Jin C.; Yan Z.-Y.; Sun B.; Yang J. Org. Lett. 2019, 21, 2064.

DOI

(e) Tao M.-L.; Wang A.-J.; Guo P.; Li W.-P.; Zhao L.; Tong J.; Wang H.-Y.; Yu Y.-B.; He C.-Y. Adv. Synth. Catal. 2022, 364, 24.

DOI

(f) Sun J.; Yang H.; Zhang B. Green Chem. 2022, 24, 858-863.

DOI

(g) Guo P.; Pu G.-L.; Wang G.-R.; Zeng L.-Y.; Li W.-P.; Li X.-F.; Zhou P.-P.; He C.-Y. Org. Lett. 2024, 26, 3097.

DOI

(h) Pu G.-L.; Song S.-Y.; Yang J.; Guo P.; Jia J.; Liu P.-J.; Li X.-F.; Liu P.; He C.-Y. Org. Chem. Front. 2024, 11, 3320.

DOI

(i) Liu L.; Pan N.; Sheng W.; Su L.; Liu L.; Dong J.; Zhou Y.; Yin S.-F. Adv. Synth. Catal. 2019, 361, 4126.

DOI

(j) Mao T.; Ma M.-J.; Zhao L.; Xue D.-P.; Yu Y.-B.; Gu J.-W.; He C.-Y. Chem. Commun. 2020, 56, 1815.

DOI

(k) Wang G.-R.; Guo P.; Pu G.L.; Wang P.; Wang A.-J.; Liu P.; Jia J.; Li X.; He C.-Y. Org. Chem. Front. 2024, 11, 4722.

DOI

[11]
(a) Wei L.; Wang J.-X.; Zhang X.-L.; Wang P.; Zhao Y.-P.; Li J.-Q.; Hou Tao.; Qu L.-L.; Shi L.-Y.; Liang X.-M.; Fang Y. J. Med. Chem. 2017, 60, 362.

DOI

(b) Dinparast L.; Hemmati S.; Zengin G.; Alizadeh A. A.; Bahadori M. B.; Kafil H. S.; Dastmalchi S. Chem. Select. 2019, 4, 9211.

(c) He M.-M.; Wang R.; Zhang R.-F.; Miao P.-C.; Wang P.-Y.; Wei Z.-Y.; Leng X.-F.; Li Y.; Fan J.-L.; Peng X.-J.; Sun W. Adv. Funct. Mater. 2023, 33, 2300780.

DOI

(d) Cheng X.-H.; Tang R.-L.; Jia H.-Z.; Feng J.; Qin J.-G.; Li Z. ACS Appl. Mater. Inter. 2012, 4, 4387.

DOI

[12]
(a) Lee S.; Sivakumar K.; Shin W.-S.; Xie F.; Wang Q. Bioorg. Med. Chem. Lett. 2006, 16, 4596.

DOI

(b) Zhang R.-X.; Jin S.-Z.; Liu Q.; Lin S.; Yan Z.-H. J. Org. Chem. 2018, 83, 13030.

DOI

(c) Xiang P.-J.; Sun K.; Wang S.; Chen X.-L.; Qu L.-B.; Yu B. Chin. Chem. Lett. 2022, 33, 5074.

DOI

(d) Nicolai J.; Fantoni T.; Butcher T. W.; Arlow S. I.; Ryabukhin S. V.; Volochnyuk D. M.; Hartwig J. F. J. Am. Chem. Soc. 2024, 146, 15464.

DOI PMID

(e) Zhang W.; Yang C.; Pan Y.-L.; Li X.; Cheng J.-P. Org. Biomol. Chem. 2018, 16, 5788.

DOI PMID

[13]
Cavallo G.; Metrangolo P.; Milani R.; Pilati T.; Priimagi A.; Resnati G.; Terraneo G. Chem. Rev. 2016, 116, 2478.

DOI

Outlines

/